1 | cumulative | 5,475 |
2 | actuarial | 458 |
3 | age-adjusted | 379 |
4 | sex-adjusted | 100 |
5 | age-standardized | 73 |
6 | cumulated | 66 |
7 | accumulative | 64 |
8 | erythemal | 29 |
9 | time-to-first | 29 |
10 | baseline-corrected | 26 |
11 | pcr-corrected | 26 |
12 | age-standardised | 25 |
13 | exposure-adjusted | 25 |
14 | gender-adjusted | 23 |
15 | 'total | 17 |
16 | time-integrated | 17 |
17 | post-avr | 14 |
18 | fracture-free | 13 |
19 | model-estimated | 10 |
20 | a-weighted | 8 |
21 | registro | 8 |
22 | severity-adjusted | 8 |
23 | 2-and | 7 |
24 | anti-pegloticase | 7 |
25 | hsclm | 7 |
26 | preswitch | 7 |
27 | ulcer-healing | 7 |
28 | comorbidity-adjusted | 6 |
29 | q³ | 6 |
30 | naloxone-induced | 5 |
31 | risk-dependent | 5 |
32 | sex-standardized | 5 |
33 | 1-and | 4 |
34 | 100-unit | 4 |
35 | hollingshead | 4 |
36 | intoxicating | 4 |
37 | leiter | 4 |
38 | long-form | 4 |
39 | mortality-adjusted | 4 |
40 | patient-wise | 4 |
41 | placebo-level | 4 |
42 | quarter-level | 4 |
43 | surface-level | 4 |
44 | vagal-related | 4 |
45 | 1-, | 3 |
46 | 3-, | 3 |
47 | 40-μg | 3 |
48 | 6-month/1-year | 3 |
49 | birthweight.the | 3 |
50 | ckdnt | 3 |
51 | ethoxylation | 3 |
52 | kattan | 3 |
53 | last-week | 3 |
54 | left-truncated | 3 |
55 | lower-than-anticipated | 3 |
56 | patients` | 3 |
57 | pre-morning | 3 |
58 | six-capsule | 3 |
59 | age-gender-adjusted | 2 |
60 | bdp-equivalent | 2 |
61 | correct-response | 2 |
62 | css׳s | 2 |
63 | cummulative | 2 |
64 | effectiveness.a | 2 |
65 | mcintosh | 2 |
66 | microtox® | 2 |
67 | multiple-point | 2 |
68 | pre-stable | 2 |
69 | radiation-absorbed | 2 |
70 | rgs-based | 2 |
71 | satietogenic | 2 |
72 | strata-specific | 2 |
73 | submutagenic | 2 |
74 | tumour-size-related | 2 |
75 | undulant | 2 |
76 | 1-,2-,3-and | 1 |
77 | 10-yrs | 1 |
78 | 19:115 | 1 |
79 | 1:115 | 1 |
80 | 20-to | 1 |
81 | 215/10,000 | 1 |
82 | adjusted-for-site | 1 |
83 | ae-adjusted | 1 |
84 | age-specified | 1 |
85 | ami- | 1 |
86 | annane | 1 |
87 | anullus | 1 |
88 | area-standardised | 1 |
89 | asthma-drug | 1 |
90 | blackest | 1 |
91 | congruent-to-incongruent | 1 |
92 | control/crb | 1 |
93 | definedcertain | 1 |
94 | ec-1y | 1 |
95 | expositional | 1 |
96 | fivefold-higher | 1 |
97 | focal-lesion | 1 |
98 | follow-up- | 1 |
99 | fsrs-estimated | 1 |
100 | hiv/syphilis | 1 |
101 | inkatha | 1 |
102 | insomniacs-to-noninsomniacs | 1 |
103 | language-level | 1 |
104 | long-term/high | 1 |
105 | mantel-haenszel-stratified | 1 |
106 | maximum-tolerable | 1 |
107 | mg/dl-the | 1 |
108 | minneci | 1 |
109 | model-projected | 1 |
110 | mortality/cancer | 1 |
111 | mucositis-bioequivalent | 1 |
112 | multiple-angle | 1 |
113 | nrsae | 1 |
114 | numberof | 1 |
115 | oaa/s50 | 1 |
116 | occurrence/the | 1 |
117 | oral-to-depot | 1 |
118 | order-parameter | 1 |
119 | organ-equivalent | 1 |
120 | oros-based | 1 |
121 | otc-recommended | 1 |
122 | over-spike | 1 |
123 | per-graft | 1 |
124 | placebo-assignment | 1 |
125 | postrecurrence | 1 |
126 | pre-tdm | 1 |
127 | preent | 1 |
128 | prevalence/expected | 1 |
129 | principle.the | 1 |
130 | respectively.statistically,2-and | 1 |
131 | selected/unselected | 1 |
132 | subantimicrobial/antiinflammatory | 1 |
133 | subprotective | 1 |
134 | surface-area-normalized | 1 |
135 | synthetically.the | 1 |
136 | teacher-driven | 1 |
137 | technique-the | 1 |
138 | time-dose-specific | 1 |
139 | titration-determined | 1 |
140 | tohcc | 1 |
141 | two-to-five-year | 1 |
142 | un-changing | 1 |
143 | uncomplete | 1 |
144 | undistinguished | 1 |
145 | us-population | 1 |
146 | wieberdink | 1 |
147 | withdrawal-ae | 1 |
1 | 'total | 17 |
2 | 1-,2-,3-and | 1 |
3 | 1-and | 4 |
4 | 1-, | 3 |
5 | 10-yrs | 1 |
6 | 100-unit | 4 |
7 | 19:115 | 1 |
8 | 1:115 | 1 |
9 | 2-and | 7 |
10 | 20-to | 1 |
11 | 215/10,000 | 1 |
12 | 3-, | 3 |
13 | 40-μg | 3 |
14 | 6-month/1-year | 3 |
15 | a-weighted | 8 |
16 | accumulative | 64 |
17 | actuarial | 458 |
18 | adjusted-for-site | 1 |
19 | ae-adjusted | 1 |
20 | age-adjusted | 379 |
21 | age-gender-adjusted | 2 |
22 | age-specified | 1 |
23 | age-standardised | 25 |
24 | age-standardized | 73 |
25 | ami- | 1 |
26 | annane | 1 |
27 | anti-pegloticase | 7 |
28 | anullus | 1 |
29 | area-standardised | 1 |
30 | asthma-drug | 1 |
31 | baseline-corrected | 26 |
32 | bdp-equivalent | 2 |
33 | birthweight.the | 3 |
34 | blackest | 1 |
35 | ckdnt | 3 |
36 | comorbidity-adjusted | 6 |
37 | congruent-to-incongruent | 1 |
38 | control/crb | 1 |
39 | correct-response | 2 |
40 | css׳s | 2 |
41 | cummulative | 2 |
42 | cumulated | 66 |
43 | cumulative | 5,475 |
44 | definedcertain | 1 |
45 | ec-1y | 1 |
46 | effectiveness.a | 2 |
47 | erythemal | 29 |
48 | ethoxylation | 3 |
49 | expositional | 1 |
50 | exposure-adjusted | 25 |
51 | fivefold-higher | 1 |
52 | focal-lesion | 1 |
53 | follow-up- | 1 |
54 | fracture-free | 13 |
55 | fsrs-estimated | 1 |
56 | gender-adjusted | 23 |
57 | hiv/syphilis | 1 |
58 | hollingshead | 4 |
59 | hsclm | 7 |
60 | inkatha | 1 |
61 | insomniacs-to-noninsomniacs | 1 |
62 | intoxicating | 4 |
63 | kattan | 3 |
64 | language-level | 1 |
65 | last-week | 3 |
66 | left-truncated | 3 |
67 | leiter | 4 |
68 | long-form | 4 |
69 | long-term/high | 1 |
70 | lower-than-anticipated | 3 |
71 | mantel-haenszel-stratified | 1 |
72 | maximum-tolerable | 1 |
73 | mcintosh | 2 |
74 | mg/dl-the | 1 |
75 | microtox® | 2 |
76 | minneci | 1 |
77 | model-estimated | 10 |
78 | model-projected | 1 |
79 | mortality-adjusted | 4 |
80 | mortality/cancer | 1 |
81 | mucositis-bioequivalent | 1 |
82 | multiple-angle | 1 |
83 | multiple-point | 2 |
84 | naloxone-induced | 5 |
85 | nrsae | 1 |
86 | numberof | 1 |
87 | oaa/s50 | 1 |
88 | occurrence/the | 1 |
89 | oral-to-depot | 1 |
90 | order-parameter | 1 |
91 | organ-equivalent | 1 |
92 | oros-based | 1 |
93 | otc-recommended | 1 |
94 | over-spike | 1 |
95 | patient-wise | 4 |
96 | patients` | 3 |
97 | pcr-corrected | 26 |
98 | per-graft | 1 |
99 | placebo-assignment | 1 |
100 | placebo-level | 4 |
101 | post-avr | 14 |
102 | postrecurrence | 1 |
103 | pre-morning | 3 |
104 | pre-stable | 2 |
105 | pre-tdm | 1 |
106 | preent | 1 |
107 | preswitch | 7 |
108 | prevalence/expected | 1 |
109 | principle.the | 1 |
110 | quarter-level | 4 |
111 | q³ | 6 |
112 | radiation-absorbed | 2 |
113 | registro | 8 |
114 | respectively.statistically,2-and | 1 |
115 | rgs-based | 2 |
116 | risk-dependent | 5 |
117 | satietogenic | 2 |
118 | selected/unselected | 1 |
119 | severity-adjusted | 8 |
120 | sex-adjusted | 100 |
121 | sex-standardized | 5 |
122 | six-capsule | 3 |
123 | strata-specific | 2 |
124 | subantimicrobial/antiinflammatory | 1 |
125 | submutagenic | 2 |
126 | subprotective | 1 |
127 | surface-area-normalized | 1 |
128 | surface-level | 4 |
129 | synthetically.the | 1 |
130 | teacher-driven | 1 |
131 | technique-the | 1 |
132 | time-dose-specific | 1 |
133 | time-integrated | 17 |
134 | time-to-first | 29 |
135 | titration-determined | 1 |
136 | tohcc | 1 |
137 | tumour-size-related | 2 |
138 | two-to-five-year | 1 |
139 | ulcer-healing | 7 |
140 | un-changing | 1 |
141 | uncomplete | 1 |
142 | undistinguished | 1 |
143 | undulant | 2 |
144 | us-population | 1 |
145 | vagal-related | 4 |
146 | wieberdink | 1 |
147 | withdrawal-ae | 1 |
1 | ami- | 1 |
2 | follow-up- | 1 |
3 | 215/10,000 | 1 |
4 | oaa/s50 | 1 |
5 | 1:115 | 1 |
6 | 19:115 | 1 |
7 | patients` | 3 |
8 | effectiveness.a | 2 |
9 | inkatha | 1 |
10 | control/crb | 1 |
11 | tohcc | 1 |
12 | strata-specific | 2 |
13 | time-dose-specific | 1 |
14 | submutagenic | 2 |
15 | satietogenic | 2 |
16 | hollingshead | 4 |
17 | radiation-absorbed | 2 |
18 | naloxone-induced | 5 |
19 | otc-recommended | 1 |
20 | undistinguished | 1 |
21 | age-specified | 1 |
22 | mantel-haenszel-stratified | 1 |
23 | titration-determined | 1 |
24 | rgs-based | 2 |
25 | oros-based | 1 |
26 | area-standardised | 1 |
27 | age-standardised | 25 |
28 | left-truncated | 3 |
29 | tumour-size-related | 2 |
30 | vagal-related | 4 |
31 | cumulated | 66 |
32 | model-estimated | 10 |
33 | fsrs-estimated | 1 |
34 | lower-than-anticipated | 3 |
35 | time-integrated | 17 |
36 | model-projected | 1 |
37 | selected/unselected | 1 |
38 | prevalence/expected | 1 |
39 | baseline-corrected | 26 |
40 | pcr-corrected | 26 |
41 | a-weighted | 8 |
42 | ae-adjusted | 1 |
43 | age-adjusted | 379 |
44 | exposure-adjusted | 25 |
45 | gender-adjusted | 23 |
46 | age-gender-adjusted | 2 |
47 | sex-adjusted | 100 |
48 | comorbidity-adjusted | 6 |
49 | mortality-adjusted | 4 |
50 | severity-adjusted | 8 |
51 | age-standardized | 73 |
52 | sex-standardized | 5 |
53 | surface-area-normalized | 1 |
54 | 1-and | 4 |
55 | 2-and | 7 |
56 | respectively.statistically,2-and | 1 |
57 | 1-,2-,3-and | 1 |
58 | withdrawal-ae | 1 |
59 | nrsae | 1 |
60 | postrecurrence | 1 |
61 | fracture-free | 13 |
62 | technique-the | 1 |
63 | mg/dl-the | 1 |
64 | principle.the | 1 |
65 | birthweight.the | 3 |
66 | synthetically.the | 1 |
67 | occurrence/the | 1 |
68 | over-spike | 1 |
69 | maximum-tolerable | 1 |
70 | pre-stable | 2 |
71 | multiple-angle | 1 |
72 | six-capsule | 3 |
73 | annane | 1 |
74 | anti-pegloticase | 7 |
75 | patient-wise | 4 |
76 | correct-response | 2 |
77 | uncomplete | 1 |
78 | adjusted-for-site | 1 |
79 | cummulative | 2 |
80 | cumulative | 5,475 |
81 | accumulative | 64 |
82 | subprotective | 1 |
83 | numberof | 1 |
84 | un-changing | 1 |
85 | ulcer-healing | 7 |
86 | pre-morning | 3 |
87 | intoxicating | 4 |
88 | asthma-drug | 1 |
89 | 40-μg | 3 |
90 | preswitch | 7 |
91 | long-term/high | 1 |
92 | mcintosh | 2 |
93 | minneci | 1 |
94 | last-week | 3 |
95 | wieberdink | 1 |
96 | actuarial | 458 |
97 | erythemal | 29 |
98 | expositional | 1 |
99 | 'total | 17 |
100 | surface-level | 4 |
101 | language-level | 1 |
102 | placebo-level | 4 |
103 | quarter-level | 4 |
104 | pre-tdm | 1 |
105 | hsclm | 7 |
106 | long-form | 4 |
107 | kattan | 3 |
108 | teacher-driven | 1 |
109 | definedcertain | 1 |
110 | focal-lesion | 1 |
111 | us-population | 1 |
112 | ethoxylation | 3 |
113 | registro | 8 |
114 | 20-to | 1 |
115 | 6-month/1-year | 3 |
116 | two-to-five-year | 1 |
117 | mortality/cancer | 1 |
118 | fivefold-higher | 1 |
119 | order-parameter | 1 |
120 | leiter | 4 |
121 | post-avr | 14 |
122 | insomniacs-to-noninsomniacs | 1 |
123 | hiv/syphilis | 1 |
124 | 10-yrs | 1 |
125 | anullus | 1 |
126 | css׳s | 2 |
127 | per-graft | 1 |
128 | 100-unit | 4 |
129 | undulant | 2 |
130 | ckdnt | 3 |
131 | risk-dependent | 5 |
132 | preent | 1 |
133 | organ-equivalent | 1 |
134 | bdp-equivalent | 2 |
135 | mucositis-bioequivalent | 1 |
136 | placebo-assignment | 1 |
137 | congruent-to-incongruent | 1 |
138 | multiple-point | 2 |
139 | oral-to-depot | 1 |
140 | blackest | 1 |
141 | time-to-first | 29 |
142 | ec-1y | 1 |
143 | subantimicrobial/antiinflammatory | 1 |
144 | 1-, | 3 |
145 | 3-, | 3 |
146 | microtox® | 2 |
147 | q³ | 6 |